Interim results from an international clinical trial with rivastigmine evaluating a 2-week titration rate in mild to severe Alzheimer's disease patients

International Journal of Geriatric Psychopharmacology

Volumn 1, Issue 3, 1998, Pages 140-144

  Vellas, B ^a   Inglis, F ^a   Potkin, S ^a   Messina, J ^a   Sain, A ^a   Koumaras, B ^a   Hartmann, R ^a   Pedersen, T ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease treatment; Antidementia medication; Dosage; Rivastigmine; Safety

Indexed keywords

CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

ABDOMINAL PAIN; ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; AUSTRIA; CANADA; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FRANCE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; TITRIMETRY; UNITED KINGDOM; UNITED STATES; VERTIGO; VOMITING;

EID: 0032457693     PISSN: 13648233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)